P/E ratio for Anavex Life Sciences (AVXL)
P/E ratio as of April 2024 (TTM): -5.17
According to Anavex Life Sciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.16667. At the end of 2022 the company had a P/E ratio of -14.2.
P/E ratio history for Anavex Life Sciences from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -14.2 | -54.81% |
| 2021 | -31.5 | 162.73% |
| 2020 | -12.0 | 136.29% |
| 2019 | -5.08 | 49.75% |
| 2018 | -3.39 | -64.19% |
| 2017 | -9.47 | -9.12% |
| 2016 | -10.4 | 17.34% |
| 2015 | -8.88 | 1292.22% |
| 2014 | -0.6379 | -73.59% |
| 2013 | -2.42 | -35.8% |
| 2012 | -3.76 | -16.74% |
| 2011 | -4.52 | -52.96% |
| 2010 | -9.61 | 7.22% |
| 2009 | -8.96 | -6.97% |
| 2008 | -9.63 | -76.16% |
| 2007 | -40.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Ligand Pharmaceuticals LGND | 45.2 | -975.28% | 🇺🇸 USA |
 Corcept Therapeutics
CORT | 25.5 | -594.43% | 🇺🇸 USA |
 Palatin Technologies PTN | -0.5845 | -88.69% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | -3.37 | -34.81% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.